MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Immune Pharmaceuticals Company Profile (NASDAQ:IMNP)

Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.25 (1,461.33% upside)

Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/4/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2015MLV & Co.Initiated CoverageBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/15/2016        
5/16/2016Q116($0.15)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.18)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/17/2015Q215($0.22)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q1($0.20)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2015($0.37)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014($0.21)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/22/2014($0.15)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/11/2014($0.15)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.14)($0.14)($0.14)
Q3 20161($0.14)($0.14)($0.14)
Q4 20161($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)
Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Immune Pharmaceuticals (NASDAQ:IMNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/26/2016Daniel Gedeon TeperCEOBuy42,000$0.59$24,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Daniel Gedeon TeperCEOBuy44,200$0.57$25,194.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Daniel Gedeon TeperCEOBuy39,400$0.62$24,428.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Daniel Gedeon TeperCEOBuy62,000$0.81$50,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Daniel Gedeon TeperCEOBuy65,400$0.76$49,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Daniel KazadoDirectorBuy150,000$0.78$117,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Daniel Gedeon TeperCEOBuy18,400$1.36$25,024.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Daniel Gedeon TeperCEOBuy18,600$1.34$24,924.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Daniel Gedeon TeperCEOBuy19,000$1.30$24,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Daniel Gedeon TeperCEOBuy40,700$1.23$50,061.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Rene Pierre AzriaDirectorBuy50,000$1.48$74,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Daniel Gedeon TeperCEOBuy7,569$1.29$9,764.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
DateHeadline
06/28/16 04:33 PMImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 04:33 PMImmune Pharma (IMNP) Announces Positive Results from Azixa Combo in Tumor Reduction - StreetInsider.com
06/23/16 07:31 AMHot Stock under Consideration: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
06/23/16 07:31 AMAnalysts Offer Insights on Healthcare Companies: Immune Pharmaceuticals Inc (NASDAQ: IMNP), Curis Inc. (NASDAQ ... - Analyst Ratings
06/23/16 07:31 AMCurrent Analysts Rating Update: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Skyline Medical Inc. (NASDAQ:SKLN) - Street Updates
06/22/16 04:42 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.27%
06/21/16 04:19 PMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14%
06/21/16 08:00 AMVista Partners Publishes June 2016 Macroeconomic & Investment Newsletter - [Marketwired] - Vista Partners has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts, investment considerations, ...
06/20/16 09:52 AMImmune Pharmaceuticals Inc (IMNP) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 07:06 AMImmune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016 - [PR Newswire] - NEW YORK, June 20, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP), "Immune", a clinical-stage biopharmaceutical company announced today that Dr. Daniel Teper, Chief Executive Officer, will be presenting at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 11:00 AM local time in the Astor room at the St Regis Hotel, New York, NY. The presentation will be webcast and available on our website (www.immunepharma.com) after the conference.
06/15/16 04:40 PMAllergan plc Ordinary Shares (NYSE:AGN) & Immune Pharmaceuticals (NASDAQ:IMNP) Investor's Alert - Wall Street 24
06/14/16 09:26 AMImmune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States
06/10/16 04:49 PMTwo Buzzers within Analysts Radar: AbbVie Inc. (NYSE:ABBV) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Street Updates
06/09/16 04:49 PMEarnings in Focus: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), QUALCOMM Incorporated (NASDAQ:QCOM) - Beacon Chronicle
06/09/16 04:49 PMEarnings in Focus: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), QUALCOMM Incorporated (NASDAQ:QCOM) - Beacon Chronicle
06/09/16 07:18 AMRecommendation Trends Analysis: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle
06/09/16 07:18 AMHC Sector News Alert: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Abbott Laboratories (NYSE:ABT) - share market updates (press release)
06/08/16 04:53 PMImmune Pharma (IMNP) Gains After Filing Joint Patent on Oral Use of Anti-Eotaxin Monoclonal Antibodies with Hadasit - StreetInsider.com
06/08/16 01:32 AM2:32 am Immune Pharma and Hadasit jointly file patent for oral use of anti-eotaxin monoclonal antibodies -
06/07/16 07:08 PMKeep Reading - [at noodls] - NEW YORK, June 7, 2016/PRNewswire / -- Immune Pharmaceuticals Inc. ('Immune'), a biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of inflammatory diseases ...
06/07/16 06:56 PMImmune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases - [PR Newswire] - NEW YORK, June 7, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. ("Immune"), a biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of inflammatory diseases and cancer, and Hadasit, the Technology Transfer company of The Hadassah Medical Organization in Jerusalem, Israel, announced today that they together filed a provisional patent on the oral use of anti-eotaxin monoclonal antibodies, including Immune's bertilimumab, for the treatment of inflammatory gastro-intestinal (GI) and liver diseases. Immune signed a licensing agreement with Hadasit in conjunction with the provisional patent filing. The data suggests that testing for eotaxin-1 serum levels, and using oral bertilimumab, a fully human monoclonal antibody, may enable the identification and treatment of patients with high-eotaxin-1-associated NASH," said Professor Yaron Ilan, Professor of Medicine, Gastro-Enterology and Liver Units and Director, Department of Medicine at Hebrew University's Hadassah Hospital in Jerusalem, Israel, who conducted the research supporting the provisional patent application.
06/06/16 08:14 AMPrice Review of Stocks: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Align Technology, Inc. (NASDAQ:ALGN) - Street Updates
06/04/16 07:21 AMImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Stock Update & Estimates - Stock Tick Tock
06/03/16 04:56 PMAnalysts Offer Insights on Healthcare Companies: Alnylam Pharmaceuticals (NASDAQ: ALNY), Immune ... - Markets.co
06/02/16 04:54 PMImmune Pharmaceuticals Inc (IMNP) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Immune Pharmaceuticals Inc (IMNP) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Immune Pharmaceuticals Inc (IMNP). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
06/02/16 04:54 PMAnalyst's Overview of Two Stocks: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Celldex Therapeutics, Inc ... - Street Updates - Analyst's Overview of Two Stocks: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Celldex Therapeutics, Inc ...Street UpdatesOn 6/1/2016, shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) rose +21.21% in trading session and finally closed at $0.40. The company most recent volume stood at 5.6 million shares as compared to average volume of 384.92 thousand shares.and more »
06/02/16 04:54 PMTwo Healthcare Most Traded Stocks: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Novartis AG (NYSE:NVS) - Is stories - Is storiesTwo Healthcare Most Traded Stocks: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Novartis AG (NYSE:NVS)Is storiesImmune Pharmaceuticals Inc. (NASDAQ:IMNP) increased +21.21% to $0.40 while traded 5.6 million shares on 6/1/2016. The stock price negotiated for value between $0.35 to $0.44 in recent trading session. During the past 52 weeks, the stock's price ...and more »
06/02/16 04:54 PMAnalytical Report of the Stock: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), Relypsa, Inc. (NASDAQ:RLYP) - Beacon Chronicle - Analytical Report of the Stock: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), Relypsa, Inc. (NASDAQ:RLYP)Beacon ChronicleLast Trade: The Company closed its last session at $0.4 with the gain of 21.21%. The market capitalization of the company is $13.51 Million, with the average Volume of 298.73K. The stock currently has its 52-Week High range of $2.23 and 52-week low ...and more »
06/02/16 07:26 AMInsiders Are Gradually Buying Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - HNN - Insiders Are Gradually Buying Immune Pharmaceuticals, Inc. (NASDAQ:IMNP)HNNAccording to the latest SEC filings, insiders at Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) have increased their position in the stock by 6.21% over the past 6 months. Insiders now own 12.40% of total outstanding shares. There are both legal and ...and more »
06/02/16 07:26 AMHC Stocks Impression: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Relypsa Inc (NASDAQ:RLYP) - share market updates (press release) - share market updates (press release)HC Stocks Impression: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Relypsa Inc (NASDAQ:RLYP)share market updates (press release)Shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) ended Wednesday session in green amid volatile trading. The shares closed up +0.070 points or 21.21% at $0.400 with 5.60 million shares getting traded. Post opening the session at $0.43, the shares ...and more »
06/01/16 04:57 PMHealthcare Stock's Latest Update : Medtronic plc (NYSE:MDT) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Is stories - Is storiesHealthcare Stock's Latest Update : Medtronic plc (NYSE:MDT) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP)Is storiesIn most recently trading session on 5/31/2016, Immune Pharmaceuticals Inc. (NASDAQ:IMNP) climbed +57.14% while traded on 2.78 million shares versus it's an average volume of 298.15 thousand shares. The company recorded the last trade with the price ...
06/01/16 04:57 PMEarnings Analysis to see: Investors Bancorp Inc. (NASDAQ:ISBC), Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Beacon Chronicle - Beacon ChronicleEarnings Analysis to see: Investors Bancorp Inc. (NASDAQ:ISBC), Immune Pharmaceuticals, Inc. (NASDAQ:IMNP)Beacon ChronicleLast Trade: The Company closed its last session at $11.97 with the loss of -0.25%. The market capitalization of the company is $4.27 Billion, with the average Volume of 3.39 Million. The stock currently has its 52-Week High range of $13.13 and 52-week ...and more »
06/01/16 07:22 AMImmune Pharmaceuticals Inc (NASDAQ:IMNP) Finally Bounces - Insider Financial - Immune Pharmaceuticals Inc (NASDAQ:IMNP) Finally BouncesInsider FinancialShares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) are finally bouncing after being on a downtrend all year. Bottom fishers are waking up to the fact that Immune is a cheap lotto ticket at current levels. We look at IMNP as a great risk/reward play ...
05/31/16 04:48 PMTake a look at Price Moves: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Alder BioPharmaceuticals, Inc. (NASDAQ ... - Street Updates - Take a look at Price Moves: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Alder BioPharmaceuticals, Inc. (NASDAQ ...Street UpdatesImmune Pharmaceuticals Inc. (NASDAQ:IMNP) diminished +0.00%, closing at $0.21 after floating between $0.20 and $0.22. The company has market capitalization of $8.60M. It has twelve month low of $0.20 and twelve month high of $2.23. The recent traded ...and more »
05/31/16 04:48 PMHealthcare Stocks to Lookout: OvaScience Inc (NASDAQ:OVAS), Immune Pharmaceuticals Inc (NASDAQ:IMNP), Array ... - The Point Review - Healthcare Stocks to Lookout: OvaScience Inc (NASDAQ:OVAS), Immune Pharmaceuticals Inc (NASDAQ:IMNP), Array ...The Point ReviewShares of OvaScience Inc (NASDAQ:OVAS) flew 9.42% to $7.55 at 12:15 PM EDT. The stock attained the volume of 1.07 Million shares recently versus average trading volume of 599,548 shares. If we take a look on its volatility, 8.51 percent was seen in a ...and more »
05/30/16 09:51 PMStock Rating Review for Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - HNN - Stock Rating Review for Immune Pharmaceuticals Inc. (NASDAQ:IMNP)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP). Covering ...
05/30/16 09:51 PMNext Weeks Broker Price Targets For Immune Pharmaceuticals Inc (IMNP) - Share Trading News - Next Weeks Broker Price Targets For Immune Pharmaceuticals Inc (IMNP)Share Trading NewsImmune Pharmaceuticals Inc has a 50 day moving average of 0.36 and a 200 day moving average of 0.57. The stock's market capitalization is 8.60M, it has a 52-week low of 0.20 and a 52-week high of 2.23. The share price of the company (IMNP) was up ...and more »
05/26/16 12:16 AMNASDAQ New Lows: Immune Pharmaceuticals, (NASDAQ:IMNP), Tuniu Corporation (NASDAQ:TOUR), America's Car ... - KC Register - NASDAQ New Lows: Immune Pharmaceuticals, (NASDAQ:IMNP), Tuniu Corporation (NASDAQ:TOUR), America's Car ...KC RegisterOn May 16, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) announced financial results for the first quarter ended March 31, 2016. Immune reported a loss attributable to common stockholders of $6.0 million, or $0.17 per share, for the quarter ended March 31 ...
05/26/16 12:16 AMEarnings Review and Stock Rundown for Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Wall Street Hints and News - Earnings Review and Stock Rundown for Immune Pharmaceuticals Inc. (NASDAQ:IMNP)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ...and more »
05/26/16 12:16 AMDrug Stocks to Watch: Alimera Sciences, (NASDAQ:ALIM), Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), Skystar Bio ... - KC Register - Drug Stocks to Watch: Alimera Sciences, (NASDAQ:ALIM), Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), Skystar Bio ...KC RegisterOn 16 May, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) reported a loss attributable to common stockholders of $6.0 million, or $0.17 per share, for the quarter ended March 31, 2016, compared to a loss attributable to common stockholders of $3.6 million, ...and more »
05/26/16 12:16 AMObserving Healthcare Stocks Update: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Immune ... - Is stories - Is storiesObserving Healthcare Stocks Update: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Immune ...Is storiesShares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) declined -9.0385% and ended at $0.2365 smaller than previous closing price of $0.2600. The total 1.08 million shares were bought and sold throughout the most recent trading session more than ...and more »
05/25/16 12:31 AMTarget Check and Stock Performance Recap Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Wall Street Hints and News - Target Check and Stock Performance Recap Immune Pharmaceuticals Inc. (NASDAQ:IMNP)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Immune Pharmaceuticals Inc.and more »
05/23/16 12:18 PMStock Rating Review for Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Wall Street Hints and News - Stock Rating Review for Immune Pharmaceuticals Inc. (NASDAQ:IMNP)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/22/16 11:33 PMRevenue Update on Immune Pharmaceuticals Inc(NASDAQ:IMNP) - Trade Calls - Revenue Update on Immune Pharmaceuticals Inc(NASDAQ:IMNP)Trade CallsImmune Pharmaceuticals Inc(NASDAQ:IMNP) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 16, 2016. Earnings per share were $-0.17. Analysts had estimated an EPS of $-0.15. Immune ...Are Analysts Bearish Immune Pharmaceuticals Inc (NASDAQ:IMNP) After Last Week?The Postall 4 news articles »
05/22/16 11:45 AMHealthcare Stock for Investors: Immune Pharmaceuticals Inc (IMNP) - News Oracle - Healthcare Stock for Investors: Immune Pharmaceuticals Inc (IMNP)News OracleBy looking at Immune Pharmaceuticals Inc (NASDAQ:IMNP) YTD (year to date) performance, the stock shows Negative value of -62.74%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the ...and more »
05/21/16 12:04 PMIMMUNE PHARMACEUTICALS INC Financials -
05/20/16 12:14 AMInsiders Are Buying Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Wall Street Hints and News - Insiders Are Buying Immune Pharmaceuticals, Inc. (NASDAQ:IMNP)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) have increased their position in the stock by 5.98%. Insiders now own 12.90% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
05/19/16 07:00 PMImmune Pharmaceuticals Inc. (NASDAQ: IMNP)'S License Agreement Could Unlock Up To $160 Million - Scibility Media - Scibility MediaImmune Pharmaceuticals Inc. (NASDAQ: IMNP)'S License Agreement Could Unlock Up To $160 MillionScibility MediaIn its recent business update, Immune Pharmaceuticals Inc. (NASDAQ: IMNP) revealed a pending agreement that could see it receive up to $160 million in payments related to worldwide license for AmiKet and AmiKet Nano. The company also reported its ...Analyst Review: Immune Pharmaceuticals Inc (IMNP)Risers & Fallersall 2 news articles »
05/18/16 11:27 AMBuy Calls Count For Immune Pharmaceuticals Inc. (NASDAQ:IMNP) At 0 - Investor Newswire - Buy Calls Count For Immune Pharmaceuticals Inc. (NASDAQ:IMNP) At 0Investor NewswireImmune Pharmaceuticals Inc. (NASDAQ:IMNP) has a total of 4 Strong Buy recommendations and 0 Strong Sell calls as of 2016-05-17. One month ago, the count of strong buy ratings were 4 and strong sell ratings were 0. The mean analyst score was 1.and more »
05/16/16 05:39 PMIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
About Immune Pharmaceuticals

Immune Pharmaceuticals logoImmune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company's oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMNP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.40
  • 50 Day Moving Average: $0.3631
  • 200 Day Moving Average: $0.4843
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $16.39M
  • Current Quarter EPS Consensus Estimate: $-0.5200 EPS
Additional Links:
Immune Pharmaceuticals (NASDAQ:IMNP) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha